Business Wire

Qure.ai Awarded EU MDR Certification for Its AI solutions

Share

Qure.ai, a leading provider of artificial intelligence (AI) software for medical imaging, today announced that its solutions were awarded the CE Class IIb certification for medical devices under the European Union Medical Device Regulation (Regulation (EU) 2017/745) (EU-MDR).

Qure.ai now offers one of the most comprehensive, certified portfolios of AI-based detection devices for radiology in the EU, spanning over 31 countries. Qure’s AI helps detect abnormalities from multiple radiology modalities including Chest X-rays, Chest CT, Head CT, and Musculoskeletal X-rays. These medical devices are cutting-edge AI software that assist radiologists in interpreting radiological scans in different healthcare settings.

Concerning the newest milestone, Prashant Warier, Co-founder and CEO of Qure.ai, said, “The EU MDR certification demonstrates our commitment to meeting the highest standards of safety and effectiveness of our products. Qure's products have undergone extensive validation and have been actively deployed globally at more than 1000 sites across 75+. Receiving EU MDR certification is a testament to the continued quality of our solutions, and it further strengthens our position as a trusted provider of AI software. The EU MDR certification will allow us to expand our reach in the EU market and enable better patient outcomes with our imaging AI solutions. We will continue to work closely with regulatory bodies to ensure compliance with the EU MDR and other relevant regulations."

EU MDR certification process is rigorous and comprehensive, ensuring that medical devices meet high safety, performance, and quality standards. Qure products are validated in 71 countries.

"Last year, Erasmus MC and Qure.ai launched an AI Innovation Centre for Medical Imaging. This innovation center will evaluate Qure's solutions for their robustness and ability to improve patient outcomes. Gauging the performance of AI solutions in different population cohorts will help create evidence for their adoption in care workflows as clinical decision support tools," says Dr. Jacob J. Visser, radiologist, chief medical information officer, and assistant-professor Value-based imaging AI at Erasmus MC. "This will give detailed insights into their use cases in disease-specific workflows like lung cancer, ER, stroke, etc., and assess the added value for patient care," he added.

The MDR certification recognizes the safety, performance, and quality of Qure.ai's AI software and confirms its compliance with EU medical device regulations. In addition, the certification assures healthcare providers and patients that Qure.ai's AI software has undergone extensive evaluation and is safe, effective, and reliable across global markets.

About Qure.ai

Qure.ai is a breakthrough Artificial Intelligence (AI) solution provider disrupting the radiology status quo by enhancing imaging accuracy and improving health outcomes with the assistance of machine-supported tools. Qure.ai taps deep learning technology to provide automated interpretation of radiology examinations like X-rays, CTs, Ultrasounds and MRI scans for time and resource-strapped medical imaging professionals—enabling faster diagnosis and speed to treatment. Qure.ai is helping to make healthcare more accessible and affordable to patients worldwide.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Queries
Amrutha Joseph | Amrutha.joseph@qure.ai | +91 8281244284

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Interactive Brokers Launches Daily Options on the CAC 40® Index2.5.2024 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the availability of Daily Options on the CAC 40® index, further expanding Interactive Brokers’ robust product suite. Daily Options on the CAC 40® index provide experienced investors with another means to execute short-term trading strategies and manage exposure to the French stock market. Milan Galik, Chief Executive Officer of Interactive Brokers, commented on the launch, "We are pleased to offer Daily Options on the CAC 40® index, which will allow our clients to balance risk and swiftly adjust their portfolios in response to market movements. At Interactive Brokers, we strive to equip our clients with an array of products to find global opportunities, and this new offering underscores our commitment to providing traders with comprehensive product solutions.” Daily Options on the CAC 40® index cater to growing demand from institutional and retail investors for options with daily expirations. The

AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity2.5.2024 16:35:00 EEST | Press release

AMRA Medical - a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms - collaborated on a study driven by University of Texas Southwestern and University Hospital Cleveland to publish new data revealing the effect of liraglutide treatment on muscle composition in adults with obesity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502719692/en/ Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher The analysis included 128 diabetes-free adults with obesity who received a lifestyle intervention in addition to being randomized to either a liraglutide (n = 73) or a placebo (n = 55) treatment group. Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the prima

Brightcove Integrates New AWS-Powered Generative AI Solution to Enhance Its Award-Winning Customer Service2.5.2024 16:00:00 EEST | Press release

Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today shared it has implemented Amazon Q Business, a new generative AI assistant on Amazon Web Services (AWS). Using its own public documentation, product, and release notes, Brightcove is leveraging the new assistant internally for real-world use cases applicable to the media and entertainment technology sector. Brightcove is tapping into the technology to build a program to equip its global services and customer success team to further bolster its award-winning customer service. As an early adopter of Amazon Q, Brightcove has launched the “Brightcove Expert Bot,” an AI-powered chatbot embedded into the internal tools, as a new resource for the customer and product support teams. Streamlining its customer support processes enables employees to quickly and effectively find relevant information, solve technical cases, analyze support requests, summarize support tickets, and use those results to help recomm

Power2Drive Europe: Contributing to the Energy Transition With Bidirectional Charging2.5.2024 15:39:00 EEST | Press release

E-mobility is about much more than driving on climate-neutral electricity from renewable sources. The batteries of electric vehicles can be used as temporary storage. And it’s not just vehicle owners who benefit from this: In the medium-term, bidirectional charging can take the burden off distribution grids while making them more flexible. Power2Drive Europe, the international exhibition for charging infrastructure and e-mobility, showcases the latest state of the art. As part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry, it will take place from June 19–21, 2024, at Messe München. The Power2Drive Europe Conference, the industry's meeting point and forum for exchange and discourse among experts, stakeholders, and thought leaders in the new mobility sector, kicks off one day earlier. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502196803/en/ Power2Drive Europe 2024 highl

Owlet Announces European Medical Certification of Dream SockⓇ2.5.2024 15:37:00 EEST | Press release

Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, announces the EU medical device certification of Dream Sock. This EU-CE-Mark certification, issued by Owlet’s EU notified body, signifies that Owlet’s Dream Sock has been assessed and certified to meet safety and health requirements set out under EU medical device legislation. With this certification, Owlet plans to expand its medical-device product portfolio to even more caregivers around the world. This EU medical device certification follows two marketing authorizations from the U.S. Food and Drug Administration (the “FDA”), for Dream Sock, with new medical technology for healthy infants over-the-counter without a prescription, and for BabySat Ⓡ, a prescription-only pulse oximeter designed for use with babies that have a pre-existing medical condition. “Our mission to be there for every parent and every baby becomes even more realized with the European medical certification for Dream Sock,” s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye